Gilder Gagnon Howe & Co. LLC cut its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 35.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,734 shares of the life sciences company’s stock after selling 932 shares during the period. Gilder Gagnon Howe & Co. LLC’s holdings in Illumina were worth $301,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in ILMN. Korea Investment CORP increased its stake in Illumina by 427.3% in the second quarter. Korea Investment CORP now owns 35,663 shares of the life sciences company’s stock valued at $6,188,000 after buying an additional 28,900 shares during the period. Sei Investments Co. increased its stake in Illumina by 96.9% in the second quarter. Sei Investments Co. now owns 143,166 shares of the life sciences company’s stock valued at $24,842,000 after buying an additional 70,469 shares during the period. Essex Investment Management Co. LLC increased its stake in Illumina by 5.4% in the second quarter. Essex Investment Management Co. LLC now owns 11,641 shares of the life sciences company’s stock valued at $2,020,000 after buying an additional 595 shares during the period. Daiwa Securities Group Inc. increased its stake in Illumina by 3.9% in the second quarter. Daiwa Securities Group Inc. now owns 4,260 shares of the life sciences company’s stock valued at $739,000 after buying an additional 160 shares during the period. Finally, State of New Jersey Common Pension Fund D increased its stake in Illumina by 20.7% in the second quarter. State of New Jersey Common Pension Fund D now owns 175,000 shares of the life sciences company’s stock valued at $30,366,000 after buying an additional 30,000 shares during the period. 93.81% of the stock is currently owned by institutional investors and hedge funds.

Shares of Illumina, Inc. (NASDAQ ILMN) opened at 194.65 on Friday. The stock has a 50 day moving average of $179.31 and a 200-day moving average of $173.49. The firm has a market capitalization of $28.42 billion, a PE ratio of 39.05 and a beta of 0.83. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $199.95.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.68 by $0.14. The company had revenue of $662 million for the quarter, compared to analyst estimates of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.86 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Gilder Gagnon Howe & Co. LLC Sells 932 Shares of Illumina, Inc. (ILMN)” was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.watchlistnews.com/gilder-gagnon-howe-co-llc-sells-932-shares-of-illumina-inc-ilmn/1472966.html.

A number of brokerages recently issued reports on ILMN. Barclays PLC reissued an “equal weight” rating and set a $150.00 price target on shares of Illumina in a report on Wednesday. Vetr raised shares of Illumina from a “hold” rating to a “buy” rating and set a $209.78 price target on the stock in a report on Wednesday. Canaccord Genuity raised shares of Illumina from a “hold” rating to a “buy” rating and increased their price target for the stock from $170.00 to $215.00 in a report on Monday. BidaskClub raised shares of Illumina from a “sell” rating to a “hold” rating in a report on Monday. Finally, Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $177.01.

In related news, Director Jay T. Flatley sold 15,000 shares of the business’s stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $175.53, for a total value of $2,632,950.00. Following the sale, the director now directly owns 534,176 shares in the company, valued at approximately $93,763,913.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Frances Arnold sold 825 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $174.77, for a total transaction of $144,185.25. Following the completion of the sale, the director now owns 8,816 shares in the company, valued at $1,540,772.32. The disclosure for this sale can be found here. Insiders have sold a total of 134,010 shares of company stock worth $23,946,015 over the last 90 days. Insiders own 1.60% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.